Israeli scientists have discovered that they might have found the first cancer treatment that will be acceptable, fast and with minimal side effects.
Jerusalem mail reported it Accelerated evolution biotechnology (AEBi) is developing a new treatment.
AEBi Chairman Dan Aridor is convinced that next year will be a complete cancer treatment.
Aridor explained that the treatment they call MuTaTo (Multi-Purpose Toxin) is at the level of cancer antibiotics – "top-of-the-line disorder technology".
The anticancer drug is based on SoAP technology belonging to the phage display group.
This includes the introduction of DNA encoding proteins, such as antibodies, into a bacteriophage – a virus that infects bacteria.
Jerusalem Post explained that MuTaTo uses a combination of multiple cancer target peptides for each cancer cell at the same time, combining it with a potent peptide toxin that specifically kills cancer cells.
Mutations will not affect treatment using at least three target peptides on the same structure with a strong toxin.
Skepticism of the industry
Les Funtleyder, Healthcare Portfolio Manager, E Squared Capital Management, CNBC the company has only tested mice so far.
"Cancer drugs can take up to six to seven years of" mouse-to-market ", even if drug manufacturers get special permissions," said Funtleyder.
He added that AEBi had not published any clinical evidence of treatment in humans.
"I think I'd like to have cancer treatment, but I don't believe them if there is no good human evidence," he said.
Dr. Benjamin Neel, Director of NYU Langone Health Cancer Center said ABC News it is very unlikely that the company has developed something that will cure all types of cancer within a year.
Duke's Health Representative refused to comment because of a lack of scientific peer review, saying it was a "non-story" until proof was given.